(VTR) Ventas - NYSE
Sector: Real Estate | Industry: REIT - Healthcare Facilities | Exchange: NYSE (USA) | Market Cap: 40.785m USD | Total Return: 34.5% in 12m
Avg Turnover: 303M
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 7
Warnings
P/E ratio 152.5
High Debt/EBITDA (5.2) with thin interest coverage (1.3)
Altman Z'' 0.02 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Ventas, Inc. (VTR) is an S&P 500 healthcare real estate investment trust (REIT) focused on the aging demographic across North America and the United Kingdom. Its portfolio of approximately 1,400 properties includes senior housing communities, outpatient medical buildings, and life science research centers. The company utilizes a proprietary data platform, Ventas OI, to optimize operational performance across its diverse asset classes.
The business operates primarily through a mix of triple-net lease structures and Senior Housing Operating Portfolio (SHOP) models, the latter of which allows the REIT to participate directly in the underlying cash flows of the facilities. As a healthcare REIT, Ventas is positioned to benefit from the long-term structural demand driven by the Silver Tsunami, as the population aged 80 and older is the fastest-growing demographic in the United States.
Investors can further examine these demographic trends and valuation metrics by visiting ValueRay. Ventas continues to leverage its scale and extensive industry relationships to expand its footprint in the longevity economy.
- Aging population demographics drive occupancy growth across senior housing operating portfolios
- Rising interest rates increase cost of capital and debt refinancing expenses
- Outpatient medical building demand provides stable cash flow and long-term lease renewals
- Medicare and Medicaid reimbursement policy changes impact healthcare facility operator profitability
- Strategic capital allocation toward life science and research centers diversifies revenue streams
| Net Income: 260.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.51 > 1.0 |
| NWC/Revenue: -18.82% < 20% (prev -13.69%; Δ -5.14% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.75b > Net Income 260.4m |
| Net Debt (12.8b) to EBITDA (2.45b): 5.20 < 3 |
| Current Ratio: 0.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (486.7m) vs 12m ago 9.03% < -2% |
| Gross Margin: -4.26% > 18% (prev 42.48%; Δ -46.74% > 0.5%) |
| Asset Turnover: 22.83% > 50% (prev 19.52%; Δ 3.31% > 0%) |
| Interest Coverage Ratio: 1.34 > 6 (EBIT TTM 1.02b / Interest Expense TTM 760.6m) |
| A: -0.04 (Total Current Assets 201.3m - Total Current Liabilities 1.36b) / Total Assets 27.7b |
| B: -0.28 (Retained Earnings -7.73b / Total Assets 27.7b) |
| C: 0.04 (EBIT TTM 1.02b / Avg Total Assets 26.9b) |
| D: 0.90 (Book Value of Equity 13.1b / Total Liabilities 14.5b) |
| Altman-Z'' = 0.02 = B |
| DSRI: 0.55 (Receivables 254.9m/382.0m, Revenue 6.13b/5.08b) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.09 (AQ_t 0.09 / AQ_t-1 0.95) |
| SGI: 1.21 (Revenue 6.13b / 5.08b) |
| TATA: -0.05 (NI 260.4m - CFO 1.75b) / TA 27.7b) |
| Beneish M = -3.79 (Cap -4..+1) = AAA |
As of June 18, 2026, the stock is trading at USD 83.89 with a total of 2,065,576 shares traded.
Over the past week, the price has changed by -2.61%,
over one month by -6.80%,
over three months by -6.05% and
over the past year by +34.49%.
Ventas has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy VTR.
- StrongBuy: 12
- Buy: 5
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 96.8 | 15.4% |
P/E Trailing = 152.5273
P/E Forward = 138.8889
P/S = 6.672
P/B = 3.1245
P/EG = 1.7374
Revenue TTM = 6.13b USD
EBIT TTM = 1.02b USD
EBITDA TTM = 2.45b USD
Long Term Debt = 12.5b USD (from longTermDebt, last quarter)
Short Term Debt = 65.0m USD (from shortLongTermDebt, last quarter)
Debt = 12.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 207.7m
Net Debt = 12.8b USD (calculated: Debt 12.9b - CCE 183.6m)
Enterprise Value = 53.5b USD (40.8b + Debt 12.9b - CCE 183.6m)
Interest Coverage Ratio = 1.34 (Ebit TTM 1.02b / Interest Expense TTM 760.6m)
EV/FCF = 112.1x (Enterprise Value 53.5b / FCF TTM 477.4m)
FCF Yield = 0.89% (FCF TTM 477.4m / Enterprise Value 53.5b)
FCF Margin = 7.78% (FCF TTM 477.4m / Revenue TTM 6.13b)
Net Margin = 4.25% (Net Income TTM 260.4m / Revenue TTM 6.13b)
Gross Margin = -4.26% ((Revenue TTM 6.13b - Cost of Revenue TTM 6.39b) / Revenue TTM)
Gross Margin QoQ = 39.56% (prev -136.0%)
Tobins Q-Ratio = 1.93 (Enterprise Value 53.5b / Total Assets 27.7b)
Interest Expense / Debt = 5.88% (Interest Expense 760.6m / Debt 12.9b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 805.9m (EBIT 1.02b * (1 - 21.00%))
Current Ratio = 0.15 (Total Current Assets 201.3m / Total Current Liabilities 1.36b)
Debt / Equity = 0.99 (Debt 12.9b / totalStockholderEquity, last quarter 13.1b)
Debt / EBITDA = 5.20 (Net Debt 12.8b / EBITDA 2.45b)
Debt / FCF = 26.71 (Net Debt 12.8b / FCF TTM 477.4m)
Total Stockholder Equity = 12.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.97% (Net Income 260.4m / Total Assets 27.7b)
RoE = 2.10% (Net Income TTM 260.4m / Total Stockholder Equity 12.4b)
RoCE = 4.11% (EBIT 1.02b / Capital Employed (Equity 12.4b + L.T.Debt 12.5b))
RoIC = 3.08% (NOPAT 805.9m / Invested Capital 26.1b)
WACC = 5.17% (E(40.8b)/V(53.7b) * Re(5.34%) + D(12.9b)/V(53.7b) * Rd(5.88%) * (1-Tc(0.21)))
Discount Rate = 5.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 8.28%
[DCF] Terminal Value 73.10% ; FCFF base≈727.1m ; Y1≈637.6m ; Y5≈515.2m
[DCF] Fair Price = N/A (negative equity: EV 8.27b - Net Debt 12.8b = -4.48b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.48 | Revenue CAGR: 13.35% | SUE: 4.0 | # QB: 7
EPS current Quarter (2026-06-30): EPS=0.11 | Chg30d=-33.33% | Revisions=-33% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.15 | Chg30d=-28.57% | Revisions=-33% | Analysts=2
EPS current Year (2026-12-31): EPS=0.54 | Chg30d=-20.15% | Revisions=-20% | GrowthEPS=+18.6% | GrowthRev=+17.9%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=-11.50% | Revisions=-33% | GrowthEPS=+58.3% | GrowthRev=+11.2%
[Analyst] Revisions Ratio: -33%